IPATF - ImmunoPrecise's 23-H7 shows promise in pre-clinical COVID-19 study

ImmunoPrecise Antibodies (IPATF) has announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.In vivo efficacy evaluation of antibody 23-H7 when administered as a passive vaccine, twenty-four hours prior to infecting Syrian hamsters with the SARS-CoV-2-D614G, resulted in undetectable replication competent virus titer in the lungs of four of the five animals 4 days post infection, with the remaining animal showing a replication competent viral titer barely above the lowest level of detection.The antibody binds to all tested variants of concern, likely because it targets a site other than the mutation prone Receptor Binding Domain/ACE2 binding interface, the company said.

For further details see:

ImmunoPrecise's 23-H7 shows promise in pre-clinical COVID-19 study